Le Lézard
Classified in: Health
Subject: SVY

Global Glaucoma Epidemiology and Patient Flow Analysis - 2017


LONDON, Nov. 16, 2017 /PRNewswire/ -- Fore Pharma announced the results of its Glaucoma patients study in a new report 'Global Glaucoma Epidemiology and Patient Flow Analysis - 2017'.

Download the full report: https://www.reportbuyer.com/product/3895288

The report provides insights into Glaucoma epidemiology, Glaucoma diagnosed patients, and Glaucoma treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Glaucoma derived from epidemiological analysis, percentage of patients diagnosed with Glaucoma, and percentage of patients treated with a therapy.

The study helps executives estimate Glaucoma market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The report provides estimates and forecasts of Glaucoma prevalence, Glaucoma diagnosis rate, and Glaucoma treatment rate for the period 2016 - 2025. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources.

Key Features of the Report:
- Glaucoma Patient Flow
- Glaucoma Prevalence
- Glaucoma Diagnosed Patients
- Glaucoma Treated Patients

Download the full report: https://www.reportbuyer.com/product/3895288

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer


These press releases may also interest you

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: